新冠病毒感染中短暂性内皮损伤与狼疮抗凝物的释放 - Suppr

Transient endothelial injury and release of lupus anticoagulant in COVID-19.

作者信息

Trimaille Antonin, Marchandot Benjamin, Oulehri Walid, Carmona Adrien, Vollmer Olivier, Poindron Vincent, Matsushita Kensuke, Sattler Laurent, Grunebaum Lelia, Korganow Anne-Sophie, Schini-Kerth Valerie, Morel Olivier

机构信息

Department of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, 1 place de l'Hôpital, 67000, Strasbourg, France.

INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, FMTS, Strasbourg, France.

出版信息

J Thromb Thrombolysis. 2022 Jan;53(1):228-230. doi: 10.1007/s11239-021-02485-5. Epub 2021 May 28.

DOI:10.1007/s11239-021-02485-5

PMID:34047937

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8160552/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f6c/8160552/a06002e138ee/11239_2021_2485_Fig1_HTML.jpg

相似文献

Transient endothelial injury and release of lupus anticoagulant in COVID-19.

J Thromb Thrombolysis. 2022 Jan;53(1):228-230. doi: 10.1007/s11239-021-02485-5. Epub 2021 May 28.

The lupus anticoagulant stimulates the release of prostacyclin from human endothelial cells.

Thromb Res. 1988 Jun 15;50(6):847-55. doi: 10.1016/0049-3848(88)90344-1.

Lupus anticoagulant in patients with COVID-19.

Int J Lab Hematol. 2021 Feb;43(1):e17-e18. doi: 10.1111/ijlh.13334. Epub 2020 Sep 11.

An 89-Year-Old Man with COVID-19-Associated Coagulopathy Presenting with a Prolonged Partial Thromboplastin Time, Lupus Anticoagulant, and a High Titer of Factor VIII Inhibitor.

Am J Case Rep. 2020 Oct 30;21:e926728. doi: 10.12659/AJCR.926728.

Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19.

N Engl J Med. 2020 Jul 16;383(3):288-290. doi: 10.1056/NEJMc2013656. Epub 2020 May 5.

Abnormal immunothrombosis and lupus anticoagulant in a catastrophic COVID-19 recalling Asherson's syndrome.

J Thromb Thrombolysis. 2021 Nov;52(4):1043-1046. doi: 10.1007/s11239-021-02444-0. Epub 2021 Apr 12.

Transient presence of lupus anticoagulant associated with mycoplasma pneumonia.

Asian Cardiovasc Thorac Ann. 2016 Mar;24(3):286-7. doi: 10.1177/0218492315625158. Epub 2016 Jan 7.

In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant.

J Clin Invest. 1999 Jul;104(1):93-102. doi: 10.1172/JCI4985.

Assessment of Lupus Anticoagulant Positivity in Patients With Coronavirus Disease 2019 (COVID-19).

JAMA Netw Open. 2020 Aug 3;3(8):e2017539. doi: 10.1001/jamanetworkopen.2020.17539.

Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus.

Clin Exp Immunol. 2001 Jul;125(1):149-54. doi: 10.1046/j.1365-2249.2001.01520.x.

引用本文的文献

Persistent Lupus Anticoagulant Positivity and Long-Term Sequelae Following Mild COVID-19.

Cureus. 2024 Oct 29;16(10):e72668. doi: 10.7759/cureus.72668. eCollection 2024 Oct.

Homozygous Factor V Leiden Complicated by Heparin-Induced Thrombocytopenia: A Case Report.

J Med Cases. 2022 May;13(5):225-228. doi: 10.14740/jmc3914. Epub 2022 Apr 23.

本文引用的文献

Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality.

Angiogenesis. 2021 Aug;24(3):505-517. doi: 10.1007/s10456-020-09762-6. Epub 2021 Jan 15.

COVID-19 is, in the end, an endothelial disease.

Eur Heart J. 2020 Sep 1;41(32):3038-3044. doi: 10.1093/eurheartj/ehaa623.

Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?

Thromb Res. 2020 Nov;195:74-76. doi: 10.1016/j.thromres.2020.07.016. Epub 2020 Jul 8.

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis.

Thromb Res. 2020 Jul;191:148-150. doi: 10.1016/j.thromres.2020.04.041. Epub 2020 Apr 30.

Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19.

N Engl J Med. 2020 Jul 16;383(3):288-290. doi: 10.1056/NEJMc2013656. Epub 2020 May 5.

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.

J Thromb Haemost. 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768. Epub 2020 Mar 13.

Systematic review of case reports of antiphospholipid syndrome following infection.

Lupus. 2016 Dec;25(14):1520-1531. doi: 10.1177/0961203316640912. Epub 2016 Apr 7.

The antiphospholipid syndrome.

N Engl J Med. 2002 Mar 7;346(10):752-63. doi: 10.1056/NEJMra002974.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Transient endothelial injury and release of lupus anticoagulant in COVID-19.

作者信息

机构信息

Department of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, 1 place de l'Hôpital, 67000, Strasbourg, France.

INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, FMTS, Strasbourg, France.

出版信息

J Thromb Thrombolysis. 2022 Jan;53(1):228-230. doi: 10.1007/s11239-021-02485-5. Epub 2021 May 28.

DOI:10.1007/s11239-021-02485-5

PMID:34047937

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8160552/

Abstract

摘要

相似文献

Transient endothelial injury and release of lupus anticoagulant in COVID-19.

J Thromb Thrombolysis. 2022 Jan;53(1):228-230. doi: 10.1007/s11239-021-02485-5. Epub 2021 May 28.

The lupus anticoagulant stimulates the release of prostacyclin from human endothelial cells.

Thromb Res. 1988 Jun 15;50(6):847-55. doi: 10.1016/0049-3848(88)90344-1.

Lupus anticoagulant in patients with COVID-19.

Int J Lab Hematol. 2021 Feb;43(1):e17-e18. doi: 10.1111/ijlh.13334. Epub 2020 Sep 11.

An 89-Year-Old Man with COVID-19-Associated Coagulopathy Presenting with a Prolonged Partial Thromboplastin Time, Lupus Anticoagulant, and a High Titer of Factor VIII Inhibitor.

Am J Case Rep. 2020 Oct 30;21:e926728. doi: 10.12659/AJCR.926728.

Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19.

N Engl J Med. 2020 Jul 16;383(3):288-290. doi: 10.1056/NEJMc2013656. Epub 2020 May 5.

Abnormal immunothrombosis and lupus anticoagulant in a catastrophic COVID-19 recalling Asherson's syndrome.

J Thromb Thrombolysis. 2021 Nov;52(4):1043-1046. doi: 10.1007/s11239-021-02444-0. Epub 2021 Apr 12.

Transient presence of lupus anticoagulant associated with mycoplasma pneumonia.

Asian Cardiovasc Thorac Ann. 2016 Mar;24(3):286-7. doi: 10.1177/0218492315625158. Epub 2016 Jan 7.

In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant.

J Clin Invest. 1999 Jul;104(1):93-102. doi: 10.1172/JCI4985.

Assessment of Lupus Anticoagulant Positivity in Patients With Coronavirus Disease 2019 (COVID-19).

JAMA Netw Open. 2020 Aug 3;3(8):e2017539. doi: 10.1001/jamanetworkopen.2020.17539.

Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus.

Clin Exp Immunol. 2001 Jul;125(1):149-54. doi: 10.1046/j.1365-2249.2001.01520.x.

引用本文的文献

Persistent Lupus Anticoagulant Positivity and Long-Term Sequelae Following Mild COVID-19.

Cureus. 2024 Oct 29;16(10):e72668. doi: 10.7759/cureus.72668. eCollection 2024 Oct.

Homozygous Factor V Leiden Complicated by Heparin-Induced Thrombocytopenia: A Case Report.

J Med Cases. 2022 May;13(5):225-228. doi: 10.14740/jmc3914. Epub 2022 Apr 23.

本文引用的文献

Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality.

Angiogenesis. 2021 Aug;24(3):505-517. doi: 10.1007/s10456-020-09762-6. Epub 2021 Jan 15.

COVID-19 is, in the end, an endothelial disease.

Eur Heart J. 2020 Sep 1;41(32):3038-3044. doi: 10.1093/eurheartj/ehaa623.

Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?

Thromb Res. 2020 Nov;195:74-76. doi: 10.1016/j.thromres.2020.07.016. Epub 2020 Jul 8.

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis.

Thromb Res. 2020 Jul;191:148-150. doi: 10.1016/j.thromres.2020.04.041. Epub 2020 Apr 30.

Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19.

N Engl J Med. 2020 Jul 16;383(3):288-290. doi: 10.1056/NEJMc2013656. Epub 2020 May 5.

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.

J Thromb Haemost. 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768. Epub 2020 Mar 13.

Systematic review of case reports of antiphospholipid syndrome following infection.

Lupus. 2016 Dec;25(14):1520-1531. doi: 10.1177/0961203316640912. Epub 2016 Apr 7.

The antiphospholipid syndrome.

N Engl J Med. 2002 Mar 7;346(10):752-63. doi: 10.1056/NEJMra002974.

Transient endothelial injury and release of lupus anticoagulant in COVID-19.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Transient endothelial injury and release of lupus anticoagulant in COVID-19.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献